Based on several preclinical studies with selective TAAR1 agonists10–12, and the recent clinical findings with SEP-3638561, TAAR1 has emerged as a promising therapeutic target for mental illness, addiction, and sleep disorders. Here, TAAR1 is linked to psychiatric disorder.